These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 3260909

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.
    Yun YS, Hargrove ME, Ting CC.
    J Immunol; 1988 Aug 15; 141(4):1390-7. PubMed ID: 3260924
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
    Peace DJ, Kern DE, Schultz KR, Greenberg PD, Cheever MA.
    J Immunol; 1988 May 15; 140(10):3679-85. PubMed ID: 2896213
    [Abstract] [Full Text] [Related]

  • 7. Lymphokine-induced cytotoxicity: requirement of two lymphokines for the induction of optimal cytotoxic response.
    Yang SS, Malek TR, Hargrove ME, Ting CC.
    J Immunol; 1985 Jun 15; 134(6):3912-9. PubMed ID: 3921614
    [Abstract] [Full Text] [Related]

  • 8. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E, Eisenthal A, Sachs D, Rosenberg SA.
    J Immunol; 1987 Mar 15; 138(6):1992-8. PubMed ID: 3493293
    [Abstract] [Full Text] [Related]

  • 9. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
    van de Griend RJ, Ronteltap CP, Gravekamp C, Monnikendam D, Bolhuis RL.
    J Immunol; 1986 Mar 01; 136(5):1700-7. PubMed ID: 3005399
    [Abstract] [Full Text] [Related]

  • 10. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T, Belfrage H, Bhiladvala P, Hedlund G.
    J Immunol; 1987 Jun 01; 138(11):3640-5. PubMed ID: 3495566
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL, Herberman RB, Olszowy MW, Cramer DV, Salup RR, Reynolds CW, Hiserodt JC.
    Cancer Res; 1988 Feb 15; 48(4):884-90. PubMed ID: 3257412
    [Abstract] [Full Text] [Related]

  • 16. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT, Eisenthal A, Rosenberg SA.
    J Immunol; 1988 Jun 01; 140(11):4062-9. PubMed ID: 3259603
    [Abstract] [Full Text] [Related]

  • 17. Induction of nonspecific cytotoxicity by monoclonal anti-T3 antibodies.
    Leeuwenberg JF, Spits H, Tax WJ, Capel PJ.
    J Immunol; 1985 Jun 01; 134(6):3770-5. PubMed ID: 2580895
    [Abstract] [Full Text] [Related]

  • 18. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB, Itoh K, Balch CM.
    J Immunol; 1987 Feb 15; 138(4):1068-73. PubMed ID: 3100627
    [Abstract] [Full Text] [Related]

  • 19. Generation and characterization of purified adherent lymphokine-activated killer cells in mice.
    Gunji Y, Vujanovic NL, Hiserodt JC, Herberman RB, Gorelik E.
    J Immunol; 1989 Mar 01; 142(5):1748-54. PubMed ID: 2783950
    [Abstract] [Full Text] [Related]

  • 20. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG, Abraham SR, Owen-Schaub LB, Hemingway LL, Hemstreet GP, DeBault LE.
    Cancer Res; 1988 Apr 15; 48(8):2184-92. PubMed ID: 3258186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.